MREO: Act Now—Secure Counsel Before Class Action Deadline!

Company Overview and Recent Developments

Mereo BioPharma Group plc (NASDAQ: MREO) is a UK-based clinical-stage biotech focused on rare diseases. The company’s lead program was setrusumab (UX143) for osteogenesis imperfecta (OI, “brittle bone” disease), developed in partnership with Ultragenyx (www.fiercebiotech.com) (www.fiercebiotech.com). In late 2025, Mereo faced a major setback: two Phase 3 trials (ORBIT and COSMIC) of setrusumab failed to meet their primary endpoints of reducing fracture rates (www.mereobiopharma.com) (www.fiercebiotech.com). While both studies showed statistically significant gains in bone mineral density, these did not translate into fewer fractures (www.mereobiopharma.com) (www.fiercebiotech.com). The surprise trial failure sent MREO’s stock price into a tailspin – shares plunged over 80% to the $0.22–$0.42 range in a single day (fintool.com) (www.biospace.com). This collapse effectively wiped out the market’s prior optimism in Mereo’s pipeline, erasing nearly $1 billion in combined value with its partner (www.biospace.com) (fintool.com).

Management immediately announced cost-cutting: “immediate reductions in our pre-commercial and manufacturing activities,” said CEO Denise Scots-Knight, to conserve cash after the setback (www.mereobiopharma.com) (www.biospace.com). The focus now pivots to Mereo’s other assets – chiefly alvelestat (MPH-966) for alpha-1 antitrypsin deficiency lung disease – as potential value drivers. However, the trial failure has spurred multiple shareholder rights law firms to launch a securities class action lawsuit against Mereo. Investors who bought MREO ADRs from June 5, 2023 through Dec 26, 2025 are being urged to seek lead-plaintiff status before the April 6, 2026 deadline (intellectia.ai). The suit alleges that Mereo made “overwhelmingly positive” but misleading statements about the Phase 3 trials’ prospects while concealing adverse facts, thereby inflating the stock price until the truth emerged (www.globenewswire.com) (intellectia.ai). Below, we dive into Mereo’s fundamentals – dividend policy, financial footing, valuation, and the risks/red flags (including the class action) – to assess the road ahead for the beleaguered biotech.

Dividend Policy and Shareholder Returns

Mereo has never paid any cash dividend on its ordinary shares and does not anticipate doing so in the foreseeable future (www.sec.gov). As a development-stage biotech with consistent net losses, the company retains all capital to fund R&D rather than returning cash to shareholders. The forward dividend yield is effectively 0%, and no dividends have been declared or paid in recent years (www.dividend.com). In fact, under UK law Mereo could not pay dividends without accumulated distributable profits – a condition it does not meet given its accumulated losses (www.sec.gov). Management’s stated policy is to reinvest any potential future earnings into advancing its pipeline, so investors should not expect income from this stock. Shareholder return thus far has come solely from stock price appreciation (or depreciation). Unfortunately, MREO’s share performance has been poor – the stock trades in the pennies after the latest collapse, and no buybacks or other capital return programs are in place.

Leverage and Debt Maturities

One silver lining for Mereo is its conservative balance sheet. The company carries minimal debt and relies primarily on equity financing to fund operations (dcfmodeling.com) (dcfmodeling.com). As of Q3 2025, total debt was just $0.4 million (all short-term) and long-term debt was virtually $0 (dcfmodeling.com). This yields a tiny debt-to-equity ratio below 1% – far lower than the ~17% biotech industry average (dcfmodeling.com). In other words, for each dollar of equity, Mereo had less than a penny of debt (dcfmodeling.com). The company had previously utilized some convertible loan notes (e.g. a Novartis note related to setrusumab’s acquisition), but these have largely converted or been extended, leaving no significant maturities in the near term (dcfmodeling.com) (www.sec.gov). Mereo’s last major financing was an equity raise of nearly $50 million in early 2025, rather than new debt . This equity-funded model avoids interest burden and restrictive covenants, which is prudent for a pre-revenue biotech. The downside, however, is dilution risk – each capital raise issues new shares, diluting existing shareholders (dcfmodeling.com) (dcfmodeling.com). Overall, Mereo’s leverage is very low, and it faces no looming debt maturities that could pressure liquidity. The absence of debt provides flexibility, but it also means the company’s fate rests on its ability to raise equity or strike partnerships to finance its drug development.

Liquidity, Cash Runway and Coverage

Liquidity does not pose an immediate crisis for Mereo, even post-trial failure – the company entered 2024 with a robust cash reserve relative to its burn rate. As of Dec 31, 2023, Mereo held $57.4 million in cash and equivalents (www.mereobiopharma.com) (www.mereobiopharma.com). Net cash burn in Q4 2023 was about $6.7 million, and full-year 2023 net loss was $29.5 million (www.mereobiopharma.com) (www.mereobiopharma.com). Management’s guidance (prior to the Phase 3 failure) was that existing cash would fund operations “into 2026” under current plans (www.mereobiopharma.com) (www.mereobiopharma.com). In the Q3 2025 update – buoyed by that year’s equity raise – the company even projected cash supporting its activities into 2027 (www.mereobiopharma.com). This runway assumes no new revenue and covers all committed clinical trials and expenses. Importantly, these estimates excluded any potential upfront cash from partnering deals or business development, which could further extend the runway (www.mereobiopharma.com).

With the setrusumab commercialization plans now shelved, Mereo is actively trimming expenses to preserve cash (www.mereobiopharma.com). The discontinuation of pre-launch and manufacturing spend for setrusumab will substantially reduce the cash burn going forward (www.mereobiopharma.com). Additionally, Mereo has received some one-time cash boosts – for example, a D&O insurance reimbursement of $2.0 million for prior legal costs and a $3.6 million ADR program reimbursement helped lower 2023 G&A expenses (www.mereobiopharma.com). These factors strengthen liquidity. Mereo has no interest-bearing debt to service, so interest coverage is not a concern – in fact, its interest expense is negligible given the almost zero debt. The key “coverage” metric to watch is cash coverage of its R&D and overhead needs, i.e. whether the company can fund its pipeline through critical milestones before needing more capital. On this front, Mereo appears to have ~2 years of runway in base-case mode. However, if it proceeds to a costly Phase 3 trial for alvelestat without a partner, its cash burn would rise and runway shorten. For now, liquidity is sufficient, but contingent on prudent cost management and/or securing partnerships to share development costs.

Pipeline and Business Outlook

Mereo’s future now hinges on its remaining pipeline beyond setrusumab. The company’s lead asset is alvelestat, an oral neutrophil elastase inhibitor being developed for Alpha-1 Antitrypsin Deficiency-related lung disease (AATD-LD). Alvelestat showed promise in Phase 2 (improvements in lung function and inflammation markers) and has received constructive feedback from regulators. Mereo has aligned with the FDA and EMA on a single Phase 3 trial design (~200 patients, 12–18 months) that, if successful, could support full approvals in both the US and EU (www.mereobiopharma.com) (www.mereobiopharma.com). Notably, the EMA indicated that improvement in lung density on CT scans (with p<0.1) might suffice as the primary endpoint for approval (www.mereobiopharma.com). Partnering discussions for alvelestat are ongoing – Mereo’s management stated they are engaged with multiple potential partner companies for alvelestat’s Phase 3 development and commercialization (www.mereobiopharma.com) (www.mereobiopharma.com). The goal was to initiate Phase 3 with a partner by around end of 2024 (www.mereobiopharma.com), but as of early 2026, no partnership has been announced. A deal could bring upfront cash and external funding of the trial, which is critical in the wake of Mereo’s cash conservation needs. Alvelestat remains the key value driver in Mereo’s pipeline; its fate will largely determine the company’s long-term prospects.

Mereo has also been monetizing or advancing several “non-core” programs to extract value without spending heavily. In August 2025, Mereo licensed out “vantictumab” – a Wnt-pathway antibody originally from OncoMed – to Ǟshibio, Inc. for development in a rare bone disease (autosomal dominant osteopetrosis 2) (www.mereobiopharma.com). Under that deal, Ǟshibio will fund global development; Mereo retained commercialization rights in Europe/UK and granted Ǟshibio rights for the US and rest of world (www.mereobiopharma.com). This effectively offloads R&D cost while preserving potential regional revenue for Mereo if the drug succeeds. Earlier, in late 2023, Mereo signed an exclusive global license agreement with ReproNovo SA for its fertility drug candidate leflutrozole (www.mereobiopharma.com). Mereo received an upfront payment (undisclosed) and is eligible for up to $64.25 million in developmental and commercial milestones, plus mid-single-digit royalties on future sales (www.mereobiopharma.com). ReproNovo will handle all further development costs for leflutrozole (www.mereobiopharma.com). These deals underscore management’s strategy to focus resources on core rare-disease programs (like alvelestat and previously setrusumab) while partnering out other assets.

Other pipeline items include etigilimab (anti-TIGIT antibody), inherited via Mereo’s 2019 merger with OncoMed. Mereo conducted a Phase 1b/2 trial (ACTIVATE) of etigilimab in combination with nivolumab (an immunotherapy) for solid tumors, but in 2022 the company chose to deprioritize oncology programs to conserve cash (www.fiercebiotech.com). Etigilimab is effectively on hold or awaiting a partner – Mereo has signaled it will pursue “business development activity around any of the non-core programs” if opportunities arise (www.mereobiopharma.com) (www.mereobiopharma.com). Additionally, Mereo previously out-licensed navicixizumab (an anti-DLL4/VEGF bispecific for cancer) to a third party (OncXerna/Feng) in 2020, and could receive milestones if that program progresses (www.sec.gov). In sum, Mereo’s pipeline has slimmed down. The high-profile failure of setrusumab leaves alvelestat as the flagship program, with partnered assets (vantictumab, leflutrozole) and shelved oncology assets as secondary upside. The company’s ability to rebound will depend on securing a partnership or positive data for alvelestat, and on any incremental milestone revenues from partnered programs. Management insists the market opportunity for alvelestat in AATD-LD is compelling and that the drug is Phase 3-ready, pending a partner (www.mereobiopharma.com) (www.mereobiopharma.com). Investors should watch for updates on alvelestat partnering in 2026, as this is critical for Mereo to create value after the setrusumab setback.

Valuation and Market Performance

After the dramatic decline in late 2025, Mereo’s valuation has been reset to deeply distressed levels. The stock currently trades around the $0.30–$0.40 per share range (ADR price), equating to a market capitalization of roughly $50–60 million. This is only marginally above Mereo’s last reported cash balance (~$48 million as of Q3 2025) (www.biospace.com). Essentially, the market is valuing the entire pipeline and technology at close to zero, implying heavy skepticism about future success. For context, just before the trial failure MREO was trading above $2/share; analysts’ consensus target was around $7.40 (reflecting high hopes for setrusumab) (dcfmodeling.com). The collapse to under 50 cents reflects a loss of ~80–90% of equity value in one blow (fintool.com) (www.biospace.com). In valuation terms, traditional metrics like P/E or EV/EBITDA are not meaningful since Mereo has no product revenue and negative earnings. Price-to-book (P/B) is more relevant: MREO now trades near 1.0x book value, as total equity was ~$46–47 million recently (simplywall.st). By comparison, prior to the setrusumab data, the stock had a large speculative premium – effectively pricing in successful trial outcomes. That premium has evaporated.

At current levels, enterprise value (EV) is very low. With market cap ~$50M and no debt, EV is only slightly below that (adjusting for cash). This means the EV is roughly equal to the cash on hand, indicating investors assign little to no value for alvelestat or other pipeline assets beyond cash. Such a “near cash” valuation can signal a deep value opportunity if the pipeline surprises to the upside, but it also signals the market’s lack of confidence. The class action and loss of credibility likely contribute to this discount. It’s worth noting that Mereo’s stock is now a “penny stock” by Nasdaq standards, which introduces its own challenges (lower liquidity, limited institutional interest, etc.). In May 2023 Mereo had faced a similar situation and temporarily regained Nasdaq compliance when its stock traded back above $1 (www.mereobiopharma.com). However, after the latest drop, MREO is again below the $1 minimum bid price required for Nasdaq Global Market listing. The company may need to consider a reverse stock split or other measures to avoid delisting if the price doesn’t recover in the coming months. In fact, Mereo already transferred its listing to the Nasdaq Capital Market in 2023 to buy more time for compliance (www.mereobiopharma.com). Overall, MREO’s valuation is now highly speculative – essentially a bet on whether management can rescue value via alvelestat or strategic actions. The upside could be significant on any positive catalyst (e.g. a lucrative partnership or takeover), but the downside risk remains that shares languish or get diluted further.

Risks and Red Flags

Mereo BioPharma carries substantial risks typical of small biotech stocks – now compounded by recent events. Key risks and red flags include:

– Class Action Lawsuit & Alleged Misconduct: The securities class action (lead plaintiff deadline April 6, 2026) is a red flag for shareholders (intellectia.ai). It alleges Mereo’s management misled investors about the Phase 3 trials, painting an overly rosy picture while withholding negative information (intellectia.ai). For example, in Q3 2025 Mereo stated it “remained confident” setrusumab would reduce fractures (www.mereobiopharma.com), which proved untrue. If evidence shows willful misrepresentation, it could damage management’s credibility and lead to legal liabilities (though D&O insurance typically covers settlement costs). At minimum, the lawsuit is a distraction for the company and underscores governance concerns.

– Pipeline Concentration & R&D Failure Risk: With setrusumab’s failure, Mereo is essentially a one-product company going forward. The fortunes of alvelestat now dominate the investment thesis. This all-or-nothing profile is risky – any setback in alvelestat (difficulty finding a partner, trial delays, or unfavorable data) would leave Mereo with little else to fall back on. The company’s other assets are partnered out or early-stage, offering only optionality. As a clinical-stage biotech, Mereo will continue to burn cash with no guarantee of ever achieving an approved product or positive earnings.

– Financial Risks – Cash Burn and Dilution: While current cash can sustain operations into 2026 (www.mereobiopharma.com), Mereo will likely need additional funding if it must independently advance alvelestat or any new program. Without revenue, the only financing options are equity or partnerships. If the stock remains deeply depressed, any equity raise would be massively dilutive to existing holders. The company’s history of repeated equity offerings (e.g. $50M in 2025) highlights this dilution risk . There is also the scenario of a fire-sale or merger if cash runs low – possibly at valuations unfavorable to current shareholders.

– Nasdaq Listing and Low Share Price: MREO’s share price ( ~$0.30–$0.40 ) is far below the $1 threshold required by Nasdaq for continued listing. This is a red flag because delisting would reduce stock liquidity and visibility. Mereo has navigated this before – in 2022–23 it faced delisting but regained compliance after shareholder activism and a cooperation agreement (www.fiercebiotech.com) (www.mereobiopharma.com). If the stock does not naturally recover above $1, the board may need to approve a reverse stock split to consolidate shares. Such corporate actions sometimes further pressure the stock. Investors should be mindful of this technical risk on top of fundamental issues.

– Management and Governance: The events of 2022–2025 raise some governance questions. An activist investor (Rubric Capital) waged a proxy battle in 2022, accusing Mereo’s board of poor capital allocation. The dispute ended with Rubric securing four board seats (www.fiercebiotech.com), suggesting significant prior shareholder discontent. While new oversight was added, the fact that Mereo proceeded to a major failure and now a class action may rekindle governance concerns. Management’s optimistic communications (now a focal point of the lawsuit) and the need for better risk disclosure will be scrutinized. Any turnover at the executive or board level in response to these pressures would add uncertainty.

– Regulatory and Development Hurdles: Even if alvelestat moves forward, it faces the usual biotech risks – clinical trial uncertainty and regulatory approval risk. The Phase 3 design for alvelestat, while agreed with regulators, still needs to demonstrate a meaningful clinical benefit in a rare disease. There’s no guarantee of success, and competing therapies or changes in regulatory stance could also impact the outlook. Moreover, Ultragenyx’s experience with setrusumab (efficacy on a surrogate endpoint not translating to clinical benefit) is a cautionary tale. Alvelestat will need to prove not only that it improves lung density or symptoms, but that these translate into better outcomes for AATD patients to secure broad adoption.

In summary, Mereo is a high-risk, high-uncertainty stock. The recent red flags – a shareholder lawsuit, an ~87% crash, and reliance on one pipeline asset – underscore that risk. Investors should perform thorough due diligence, and as the class-action tagline suggests, consider their legal options if significant losses were incurred.

Open Questions and What to Watch

Given the fluid situation, several open questions remain about Mereo’s future:

– Can Mereo Secure a Partner for Alvelestat? A partnership is crucial to fund the Phase 3 trial and validate alvelestat’s potential. Will a larger pharma strike a deal in 2026, and on what terms (upfront payment, profit split)? The timing of any partnership announcement will be a major catalyst for the stock.

– What Are the Next Steps for Setrusumab (if any)? Ultragenyx and Mereo indicated they will analyze the Phase 3 data further (www.fiercebiotech.com) (www.fiercebiotech.com). Is there a path forward in a subset of patients (e.g. pediatric OI) or with an alternate endpoint? Or will the program be abandoned entirely? Any decision here could influence whether Mereo retains some hope (however slim) of future milestone payments from setrusumab.

– How Will the Class Action Resolve? The outcome of the lawsuit is uncertain – will Mereo seek an early settlement, fight the claims in court, or face an extended legal battle? Also, will the allegations prompt any internal changes (improved disclosure practices or even leadership changes)? Investors should monitor company statements regarding the litigation and any related SEC inquiries.

– Does Mereo Have Strategic Alternatives? In light of the stock price collapse, is Mereo exploring strategic alternatives like a merger or sale? The company’s ~$50M cash and Nasdaq listing could make it a reverse merger candidate for another biotech, or a takeover target if alvelestat is viewed attractively by a suitor. Any indication of strategic review or banker engagement would be notable.

– Will Nasdaq Compliance Be Maintained? If the share price doesn’t rebound above $1, what is Mereo’s plan to remain listed? Investors should watch for a possible reverse stock split proposal or other Nasdaq communications. A formal notice of non-compliance would give a timeframe (often 180 days) to cure the deficiency – a clock that may already be ticking.

– How Long Will the Cash Last and What Cuts Will be Made? Management guided a runway into 2026 (www.mereobiopharma.com), but with the recent cost cuts, could the cash now stretch further? Conversely, if a partnership doesn’t materialize, will Mereo downsize operations or shelve projects to extend the runway? Updates on quarterly cash burn and any workforce reductions will be key to gauge the remaining runway under various scenarios.

– Can Mereo Rebuild Investor Trust? Finally, an intangible but important question: after this saga, can management regain the market’s confidence? Positive execution on alvelestat (regulatory progress or partnership) would help, as would more cautious and transparent communications going forward. The board composition, including activist-appointed directors, will play a role in steering the company through this rebuilding phase.

Bottom Line: Mereo BioPharma now finds itself in a precarious position – essentially a cash-rich shell with one main clinical asset. The upcoming class action deadline highlights the urgency for affected shareholders to act, but from an investment standpoint the focus is on whether Mereo can extract value from alvelestat or other assets before the cash runs out. The stock’s steep discount reflects the many risks ahead. Only decisive positive developments (like a strong partnership deal or trial success) are likely to turn the tide. Until then, caution is warranted, and stakeholders will be closely watching how Mereo’s next chapters unfold in 2026.

Sources: Mereo BioPharma SEC filings and press releases; company investor updates; GlobeNewswire/PR Newswire class action notices (www.globenewswire.com) (intellectia.ai); FierceBiotech and BioSpace news reporting (www.biospace.com) (www.fiercebiotech.com); DCFmodeling and SimplyWallSt financial data (dcfmodeling.com) (simplywall.st); and other market intelligence as cited above. All information is as of March 2026 and is subject to change with new disclosures.

For informational purposes only; not investment advice.